A	B	C
1	Main
2		Brand	Jaypirca, fka LOXO-305
3		Generic	pirtobrutinib
4		Indication	3L+ CLL/SLL accelerated approval
5		MOA	non-covalent BTK inhibitor
6		Safety	fatigue, neutropenia, diarrhea, cough, contusion
7		Clinical Trials
8			Phase III CLL-322 2L CLL piro+ven+ritux vs. veneto_ritux
9
10
11
12			Phase I/II "BRUIN" n=282 2L+ MCL, CLL/SLL, other NHL
13			median 4L, mPFS 19.4 months, mOS not estimable
14			79.7% ORR (including PR-L) with prior covalent + BCL-2
15			83.1% ORR (including PR-L) with BCL-2 naïve